{"organizations": [], "uuid": "ffc6707235e5a1cb2c13cd1ba3385cffba72e5f1", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-ema-to-review-dupixent-as-potentia/brief-ema-to-review-dupixent-as-potential-treatment-for-inadequately-controlled-moderate-to-severe-asthma-idUSFWN1RG018", "country": "US", "domain_rank": 408, "title": "BRIEF-‍EMA To Review Dupixent As Potential Treatment For Inadequately Controlled Moderate-To Severe Asthma​", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-03T08:06:00.000+03:00", "replies_count": 0, "uuid": "ffc6707235e5a1cb2c13cd1ba3385cffba72e5f1"}, "author": "", "url": "https://www.reuters.com/article/brief-ema-to-review-dupixent-as-potentia/brief-ema-to-review-dupixent-as-potential-treatment-for-inadequately-controlled-moderate-to-severe-asthma-idUSFWN1RG018", "ord_in_thread": 0, "title": "BRIEF-‍EMA To Review Dupixent As Potential Treatment For Inadequately Controlled Moderate-To Severe Asthma​", "locations": [], "entities": {"persons": [{"name": "ina", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "controlled moderate-to severe asthma​ reuters", "sentiment": "none"}, {"name": "regeneron pharmaceuticals inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 3 (Reuters) - Regeneron Pharmaceuticals Inc:\n* ‍EMA TO REVIEW DUPIXENT® (DUPILUMAB) AS POTENTIAL TREATMENT FOR INADEQUATELY CONTROLLED MODERATE-TO-SEVERE ASTHMA​\n* ‍EUROPEAN MEDICINES AGENCY (EMA) HAS ACCEPTED FOR REVIEW AN APPLICATION FOR DUPIXENT​ Source text for Eikon: Further company coverage:\n ", "external_links": [], "published": "2018-04-03T08:06:00.000+03:00", "crawled": "2018-04-03T08:42:07.008+03:00", "highlightTitle": ""}